Tumor microenvironment in T-Cell lymphomas

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


T-cell lymphomas (TCL) are uncommon non-Hodgkin lymphomas that often have an aggressive clinical course. Patients typically have limited treatment options upon relapse and a dismal prognosis after progression despite newly approved therapies. New therapeutic approaches for these orphan diseases are very much needed and a greater understanding of the role of nonmalignant immune cells in the tumor microenvironment may allow for an improved antitumor immune response. The tumor microenvironment is a key component in tumor evasion and typically results in an ineffective T-cell response to the tumor cells despite a significant inflammatory response. A better understanding of the tumor microenvironment therefore, in an effort to overcome the barriers to an effective immune response, would help in developing novel therapeutic approaches to treat and improve outcomes of these diseases. Immune checkpoint blockade to reinvigorate suppressed T-cell, or modulation of the CD47-SIRPalpha axis to promote macrophage phagocytosis, would be such targets. However, whether modulating the immune response using each pathway alone or whether a combination approach is necessary has yet to be determined.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Number of pages14
StatePublished - 2019

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • CD47-SIRPalpha axis
  • Checkpoint blockade
  • Helper T-cells
  • Immunotherapy
  • Regulatory T-cells
  • T-cell lymphoma
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Tumor microenvironment in T-Cell lymphomas'. Together they form a unique fingerprint.

Cite this